Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a patent No. 8,017,576 to NephRx's NX002.
Subscribe to our email newsletter
NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.
The patent covers methods and compositions to treat mucositis.
NephRx president and CEO James Koziarz said that this new patent for oral mucositis further confirms the potential utility of NX002 as a treatment for a number of serious disorders of the gastrointestinal system.
"Oral mucositis is a painful and debilitating side effect of cancer therapy that can be dose-limiting, jeopardizing patients’ chances for successful treatment," Koziarz added.